Targeted Sequencing using Custom NEBNext Direct Panels

Get in Touch

Our Locations

Targeted Sequencing using Custom NEBNext Direct Panels

Addressing common issues in next generation sequencing assays

Have you considered incorporating genomics into your clinical trial design? In this presentation, you will explore the key attributes of genomic assays in support of clinical development.

You will also be introduced to the NEBNext Direct methodology, which addresses common issues that plague next generation sequencing (NGS) assays.

Q²Solutions offers a comprehensive suite of genomic services to help you design and execute smarter trials. Download our presentation to learn more.

Author:
Jennifer Sims, Ph.D., Manager, Assay Development, Translational Genomics

Related Services & Solutions

Related Thought Leaders Insights

Scientific Poster

Robust performance of single-cell multiomic analysis (CITE-Seq) demonstrated across multiple locations, replicates, and donors on challenging cryopreserved PBMC and BMMC samples

Q² Solutions is the first and only service provider to achieve the exclusive certified service partnership for CITE-Seq scRNA-Seq with BioLegend. Describes CITE-Seq performance expectations for...

Brochure

Challenging Bioanalytical Work

If you’re looking for solutions to analytical challenges, you’ve come to the right place. Our highly trained scientists partner with you to provide a well-planned strategy, no matter where you are in...

Factsheet

CNS Biomarkers

Rules-Based Medicine, a Q² Solutions company, offers ultrasensitive immunoassays – including beta-amyloids, GFAP, NF-L, and pTaus – for the development of diagnostics and therapeutics for Alzheimer’s...